Victory buys bankrupt Middlebrook's assets

Middlebrook Pharmaceuticals, which filed for Chapter 11 bankruptcy last month, announced today that Victory Pharma is purchasing all the company's assets for $17.1 million. Middlebrook has been on the rocks for some time now. The Westlake, TX-based company has been through three rounds of layoffs, which claimed the jobs of its entire field sales force as well as CEO John Thievon. With its sales force gone, MiddleBrook has been relying on to commercialize Moxatag, an antibiotic for strep throat, which is the company's only marketed drug.

"During the Bankruptcy Court supervised process, we remain committed to continuing to promote Moxatag utilizing our third party partner's electronic promotion program and maintaining Moxatag and Kefelx product availability to our trade sales customers," says David Becker, MiddleBrook's acting CEO. San Diego-based Victory Pharma is developing products to treat pain and related conditions.

- take a look at Middlebrook's release

Suggested Articles

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.

Gilead is considering repositioning NUC inhibitor remdesivir as a treatment for the coronavirus now sweeping across parts of China.

Ipsen has paused a phase 3 trial of palovarotene after an interim analysis found it is unlikely to meet its primary efficacy endpoint.